Summary of Study ST000166

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000144. The data can be accessed directly via it's Project DOI: 10.21228/M8C01P This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST000166
Study TitleCardiac Resynchronization Therapy Induces Adaptive Metabolic Transitions in the Metabolomic Profile of Heart Failure
Study Typeintervention
Study SummaryThis prospective study consisted of 24 patients undergoing CRT for advanced HF and 10 control patients who underwent catheter ablation for supraventricular arrhythmia but not CRT. Blood samples were collected before and 3 months after CRT. Metabolomic profiling of plasma samples was performed using gas chromatography–mass spectrometry and nuclear magnetic resonance.
Institute
Mayo Clinic
DepartmentDepartment of Medicine
Last NameCha
First NameYong-Mei
Emailycha@mayo.edu
Submit Date2015-05-14
Num Groups3
Total Subjects24
Raw Data AvailableNo
Raw Data File Type(s)d
Analysis Type DetailGC-MS
Release Date2015-06-28
Release Version1
Yong-Mei Cha Yong-Mei Cha
https://dx.doi.org/10.21228/M8C01P
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR000144
Project DOI:doi: 10.21228/M8C01P
Project Title:Cardiac Resynchronization Therapy Induces Adaptive Metabolic Transitions in the Metabolomic Profile of Heart Failure
Project Summary:Background: Heart failure (HF) is associated with ventricular dyssynchrony and energetic inefficiency, which can be alleviated by cardiac resynchronization therapy (CRT). The aim of this study was to determine the metabolomic signature in HF and its prognostic value for the response to CRT. Methods: This prospective study consisted of 24 patients undergoing CRT for advanced HF and 10 control patients who underwent catheter ablation for supraventricular arrhythmia but not CRT. Blood samples were collected before and 3 months after CRT. Metabolomic profiling of plasma samples was performed using gas chromatography–mass spectrometry and nuclear magnetic resonance. Results: The plasma metabolomic profile was altered in the HF patients, with a distinct panel of metabolites, including Krebs cycle and lipid, amino acid, and nucleotide metabolism. CRT improved the metabolic profile. The succinate/glutamate ratio, an index of Krebs cycle activity, improved from 0.58?0.13 to 2.84?0.60 (P<.05). The glucose/palmitate ratio, an indicator of the balance between glycolytic and fatty acid metabolism, increased from 0.96?0.05 to 1.54?0.09 (P<.01). Compared with the nonresponders to CRT, the responders had a distinct baseline plasma metabolomic profile, including higher isoleucine, phenylalanine, leucine, glucose, and valine levels and lower glutamate levels at baseline (P<.05). Conclusion: CRT improves plasma metabolomic profile of HF patients indicating harmonization of myocardial energy substrate metabolism. CRT responders may have a favorable metabolic profile as a potential biomarker for predicting CRT outcome.
Institute:Mayo Clinic
Department:Department of Medicine
Last Name:Cha
First Name:Yong-Mei
Email:ycha@mayo.edu

Subject:

Subject ID:SU000185
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Group State
SA0090423M_283M Res
SA0090433M_263M Res
SA0090443M_303M Res
SA0090453M_343M Res
SA0090463M_23M Res
SA0090473M_203M Res
SA0090483M_233M Res
SA0090493M_73M Res
SA0090503M_63M Res
SA0090513M_93M Res
SA0090523M_43M Unres
SA0090533M_53M Unres
SA0090543M_333M Unres
SA0090553M_103M Unres
SA0090563M_273M Unres
SA0090573M_143M Unres
SA0090583M_83M Unres
SA0090593M_173M Unres
SA0090603M_243M Unres
SA00906119_1Control Control
SA00906222_1Control Control
SA00906329_1Control Control
SA00906418_1Control Control
SA00906521_1Control Control
SA00906616_1Control Control
SA00906711_1Control Control
SA00906812_1Control Control
SA00906913_1Control Control
SA00907015_1Control Control
SA0090713_1HF Res
SA00907228_1HF Res
SA00907330_1HF Res
SA0090747_1HF Res
SA0090759_1HF Res
SA00907625_1HF Res
SA0090776_1HF Res
SA00907834_1HF Res
SA00907926_1HF Res
SA0090802_1HF Res
SA00908123_1HF Res
SA00909320_1HF uc
SA00909432_1HF uc
SA00908214_1HF Unres
SA00908310_1HF Unres
SA0090848_1HF Unres
SA0090858_1AHF Unres
SA0090861_1HF Unres
SA0090875_1HF Unres
SA00908817_1HF Unres
SA00908927_1HF Unres
SA0090904_1HF Unres
SA00909133_1HF Unres
SA00909224_1HF Unres
Showing results 1 to 53 of 53

Collection:

Collection ID:CO000171
Collection Summary:Blood samples were taken from a peripheral vein. These blood samples (5 mL) were collected into EDTA tubes containing 100 ?L of injected stop solution (dipyrimidole,10 ?M; EHNA, 5 ?M; iodotubercidin, 2 ?M; AOPCP, 50 ?M, in 0.9% NaCl) to reduce blood nucleotide metabolism; stored on ice; and then centrifuged at 3,200 rpm for 10 minutes at 4°C. Plasma aliquots were stored at ?80°C until analyses.
Sample Type:Blood

Treatment:

Treatment ID:TR000191
Treatment Summary:Heart failure|3-month follow up after cardiac resynchronization therapy (CRT)|Controls
Treatment Protocol Comments:All HF patients underwent a baseline evaluation before CRT, including assessment of New York Heart Association (NYHA) functional class, concomitant cardiovascular conditions (e.g., hypertension, coronary artery disease, and diabetes mellitus), electrocardiographic QRS duration and morphologic characteristics, and transthoracic echocardiography. Echocardiographic parameters included LV end-systolic and diastolic dimensions, LVEF, and pulmonary artery systolic pressure. Medication use was recorded and confirmed that patients were taking optimal medication dose for HF. Patients continued on stable medication dosage during the study.|The HF patients returned for a clinical follow-up 3 months after CRT. The NYHA functional class was reassessed, and echocardiography was repeated.|Ten age-matched control patients underwent catheter ablation for supraventricular arrhythmia with a normal left ventricular ejection fraction (LVEF) of greater than 55%.

Sample Preparation:

Sampleprep ID:SP000185
Sampleprep Summary:For gas chromatography–mass spectrometry (GC-MS), plasma (100 ?L) was extracted using a 900-?L methanol:water (8:1, v/v) mixture containing 5 ?g internal standard, myristic-d27 acid, at ambient temperature 33. Supernatant (900 ?L) was transferred and completely dried in a vacuum concentrator. Subsequently, the tubes were methoximated and derivatized and then analyzed using an Agilent 6890 GC oven with Agilent 5973 MS 34.
Sample Treatment and Instrumental Conditions for 1H NMR Metabolomic Analysis
For nuclear magnetic resonance (NMR) imaging, plasma (60 ?L) was diluted 140 ?L with 0.2M phosphate buffer (pH 7.4):D2O containing a mixture of 16 mM formate and 4 mM TSP (1:1, v/v). After filtering (0.22 ?m), the samples were transferred into a 3-mm-diameter NMR tube. High-resolution 1H NMR spectra were acquired at 600 MHz on a Bruker Avance III 600 spectrometer. Spectra peaks were identified according to Chenomx NMR Suite 6.1 software and data in the literature 35, 36.
Sampleprep Protocol Filename:Methods-For-Upload.docx

Combined analysis:

Analysis ID AN000259
Analysis type MS
Chromatography type GC
Chromatography system Agilent 6890 GC
Column
MS Type EI
MS instrument type Single quadrupole
MS instrument name Agilent 5973
Ion Mode POSITIVE
Units Peak area

Chromatography:

Chromatography ID:CH000183
Chromatography Summary:For gas chromatographymass spectrometry (GC-MS), plasma (100 ?L) was extracted using a 900-?L methanol:water (8:1, v/v) mixture containing 5 ?g internal standard, myristic-d27 acid, at ambient temperature 33. Supernatant (900 ?L) was transferred and completely dried in a vacuum concentrator. Subsequently, the tubes were methoximated and derivatized and then analyzed using an Agilent 6890 GC oven with Agilent 5973 MS 34.
Sample Treatment and Instrumental Conditions for 1H NMR Metabolomic Analysis
For nuclear magnetic resonance (NMR) imaging, plasma (60 ?L) was diluted 140 ?L with 0.2M phosphate buffer (pH 7.4):D2O containing a mixture of 16 mM formate and 4 mM TSP (1:1, v/v). After filtering (0.22 ?m), the samples were transferred into a 3-mm-diameter NMR tube. High-resolution 1H NMR spectra were acquired at 600 MHz on a Bruker Avance III 600 spectrometer. Spectra peaks were identified according to Chenomx NMR Suite 6.1 software and data in the literature 35, 36.
Instrument Name: Agilent 6890 GC
Chromatography Type:GC

MS:

MS ID:MS000209
Analysis ID:AN000259
Instrument Name:Agilent 5973
Instrument Type:Single quadrupole
MS Type:EI
Ion Mode:POSITIVE
  logo